Type 1 Diabetes
A Study of LY900014 in a Medtronic Pump
The purpose of this study is to compare the study drug LY900014 to insulin lispro (Humalog) when both are delivered by the Medtronic MiniMed 670G System in adults with type 1 diabetes (T1D). The study will consist of two treatment periods of 4 weeks.
The results of this study are not yet available.
The study will last about 13 weeks and may include up to 6 live visits and 5 phone visits.
Here you can find out a bit more about the requirements for volunteers who took part in this study
• Participants must have been diagnosed with type 1 diabetes and have been using insulin continuously for at least 12 months
• Participants must be using an insulin pump with “rapid-acting insulin” for at least 6 months and the same “rapid acting insulin” for at least the past 30 days
• Participants must have hemoglobin A1c (HbA1c) values ≥6.0% and ≤8.0%
• Participants must have been using the MiniMed 670G insulin pump for at least the past 90 days
• Participants must use their Guardian (3) sensor at least an average of 75% of the time and remain in Auto Mode an average of 70% of the time
• Participants must not have had more than 1 emergency treatment for very low blood glucose or any hospitalizations for poor glucose control (very high blood sugar or diabetic ketoacidosis) in the last 6 months
• Participants must not have significant abnormal accumulation of fat, loss of fat tissue, or scars just under the skin in areas of infusion or have a history of an infection at an infusion site within 90 days prior to screening
• Participants must not have a total daily insulin dose >100 units
• Participants must not be receiving any oral or injectable medication intended for the treatment of diabetes other than rapid-acting analog insulin via CSII in the 30 days prior to screening
• Participants must not have major problems with their heart, kidneys, liver, or have a blood disorder